Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03946670
Title A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Acronym STIMULUS-MDS1
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT

Facility Status City State Zip Country Details
City of Hope National Medical Center Medical Oncology & Therapeutic Duarte California 91010 United States Details
Yale University School Of Medicine New Haven Connecticut 06520 United States Details
Dana Farber Cancer Institute Centerfor Sarcoma&BoneOncology Boston Massachusetts 02215 United States Details
The Cancer Institute of New Jersey The Cancer Institute of NJ New Brunswick New Jersey 08901 United States Details
Ohio State Comprehensive Cancer Center/James Cancer Hospital SC BCL201X2102C Columbus Ohio 73210 United States Details
Mary Crowley Cancer Research Dallas Texas 75251 United States Details
Novartis Investigative Site Vienna 1140 Austria Details
Novartis Investigative Site Brasschaat 2930 Belgium Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Toronto Ontario M5G 1Z6 Canada Details
Novartis Investigative Site Quebec G1J 1Z4 Canada Details
Novartis Investigative Site Brno - Bohunice 625 00 Czechia Details
Novartis Investigative Site Praha 12808 Czechia Details
Novartis Investigative Site Toulouse 31059 France Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Leipzig 04103 Germany Details
Novartis Investigative Site Alexandroupolis Evros 681 00 Greece Details
Novartis Investigative Site Larissa GR 411 10 Greece Details
Novartis Investigative Site Patras 265 00 Greece Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Debrecen 4032 Hungary Details
Novartis Investigative Site Nyiregyhaza 4400 Hungary Details
Novartis Investigative Site Firenze FI 50134 Italy Details
Novartis Investigative Site Milano MI 20162 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Reggio Calabria RC 89124 Italy Details
Novartis Investigative Site Roma RM 00133 Italy Details
Novartis Investigative Site Fukuoka city Fukuoka 812-8582 Japan Details
Novartis Investigative Site Fukushima city Fukushima 960 1295 Japan Details
Novartis Investigative Site Gifu shi Gifu 500 8513 Japan Details
Novartis Investigative Site Isehara Kanagawa 259-1193 Japan Details
Novartis Investigative Site Kumamoto-city Kumamoto 860-0008 Japan Details
Novartis Investigative Site Sendai-shi Miyagi 983 8520 Japan Details
Novartis Investigative Site Nagasaki-city Nagasaki 852-8501 Japan Details
Novartis Investigative Site Bunkyo ku Tokyo 113-8677 Japan Details
Novartis Investigative Site Osaka 545-8586 Japan Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 06351 Korea, Republic of Details
Novartis Investigative Site Malaga Andalucia 29010 Spain Details
Novartis Investigative Site Santander Cantabria 39008 Spain Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
Novartis Investigative Site Kaohsiung 83301 Taiwan Details
Novartis Investigative Site Taipei 10002 Taiwan Details
Novartis Investigative Site Izmir 35040 Turkey Details
Novartis Investigative Site Kocaeli 41380 Turkey Details
Novartis Investigative Site Samsun 55139 Turkey Details
Novartis Investigative Site Manchester M20 4BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field